Navigation Links
Long-term 12-month safety data on ADHD patch DAYTRANA
Date:10/26/2007

BOSTON OCTOBER 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom, reported investigator Frank A. Lpez, M.D., neurodevelopmental pediatrician at the Childrens Developmental Center, Winter Park, Fla. Importantly, this year-long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies.

Shires DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping.

Lpez added, DAYTRANAs novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their childrens changing schedules.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

The study was supported by funding from Shire.


'/>"/>

Contact: Jennifer Anello
212-601-8132
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Small lumps in breast if not treated may cause long-term harm
4. Lung Therapy Found To Have Long-Term Side Effects
5. Long-Term Benefits Of Statins Questioned
6. Long-term use of calcium supplements to prevent colon cancer
7. Survivors of childhood cancer may have long-term health problems
8. Long-term Care Should Be A Planned Affair
9. Pfizer vouches safety of long-term inhaled insulin.
10. Clue to Link Between Obesity and Long-Term Memory Discovered
11. Drug Regulators Need To Think In Long-Term, Say Charities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... MEDIA OPPORTUNITY: , Save Our ... interview citizens on why they are rallying against Mayo Clinic. Specifically, media can talk ... against Dr. Noseworthy’s (CEO) decision to close the Albert Lea hospital. , The rally ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... buildings, and Richard Pedranti Architect (RPA), a full-service architecture firm focusing ... partner’s Solsken Line of Model Homes . Independently, Ecocor and RPA have ...
(Date:9/22/2017)... ... ... Happy Living’s mission - to improve the health and wellbeing of the ... delicious worlds of theatre and wines. , After watching Scott Barry perform on ... play into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ) was published on ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... of independent freestanding emergency rooms is celebrating the one year anniversary of its ... our facility opening,” said Dr. Otinwa, Facility Medical Director of First Choice Emergency ...
(Date:9/22/2017)... ... 22, 2017 , ... “Letters From Home”: a moving compilation of letters ... to God. “Letters From Home” is the creation of published author, John Allred, a ... of Jerry Savelle Ministries International, who has traveled and ministered on four continents. , ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
(Date:9/7/2017)... 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting at ... Rodman & Renshaw 19 th Annual Global Investment Conference ... p.m. Pacific time). The conference is being held at the ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology: